mafodotin plus rituximab, ifosfamide, carboplatin, and etoposide chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant
|Effective start/end date||9/1/15 → 3/30/20|
- Seattle Genetics, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.